Evolus (NASDAQ:EOLS) Releases Quarterly Earnings Results, Misses Estimates By $0.09 EPS

Evolus (NASDAQ:EOLS) released its quarterly earnings results on Tuesday. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.09), Zacks reports. Evolus had a negative return on equity of 847.60% and a negative net margin of 22.33%.

Evolus Trading Up 0.1 %

Shares of EOLS stock traded up $0.01 on Tuesday, reaching $14.35. 911,732 shares of the stock were exchanged, compared to its average volume of 593,467. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. Evolus has a one year low of $9.25 and a one year high of $17.82. The stock has a market cap of $908.66 million, a PE ratio of -15.77 and a beta of 1.33. The stock has a 50 day moving average price of $12.72 and a 200 day moving average price of $14.08.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on EOLS. HC Wainwright restated a “buy” rating and set a $27.00 target price on shares of Evolus in a report on Friday, February 14th. Barclays increased their price objective on shares of Evolus from $20.00 to $22.00 and gave the stock an “overweight” rating in a report on Monday, January 27th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Evolus in a research note on Tuesday, January 21st.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.